Revenue recognition will begin in the second quarter of 2009 on a proportional basis as services are performed on each project. The backlog of the company was approximately $31 million at April 15, 2009.
David Ginsberg, CEO of Encorium, said: “The contracts represent a continuation of our success in the field of vaccines and oncology and we plan to continue to further develop our already significant expertise in the therapeutic arenas of vaccines as well as oncology.”